1.65p-0.04 (-2.42%)25 Mar 2025, 16:06
Jump to:
Cizzle Biotechnology Holdings PLC Fundamentals
Company Name | Cizzle Biotechnology Holdings PLC | Last Updated | 2025-03-25 |
---|---|---|---|
Industry | Biotechnology | Sector | Healthcare |
Shares in Issue | 396.392 m | Market Cap | £6.38 m |
PE Ratio | 1.68 | Dividend per Share | 0 |
Dividend Yield | 0 | Dividend Cover | 0 |
EPS | -£0.01 | EPS Growth (%) | 0 |
PEG | 0 | DPS Growth (%) | 0 |
Debt Ratio | 0 | Debt Equity Ratio | 0 |
Asset Equity Ratio | 1.1625 | Cash Equity Ratio | 1.0277 |
Quick Ratio | 7.1550 | Current Ratio | 7.16 |
Price To Book Value | 8.2372 | ROCE | 0 |
Cizzle Biotechnology Holdings PLC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|
Cizzle Biotechnology Holdings PLC Company Financials
Assets | 2023 | 2022 |
---|---|---|
Tangible Assets | 0 | 0 |
Intangible Assets | 0 | £2.08 m |
Investments | 0 | 0 |
Total Fixed Assets | 0 | £2.08 m |
Stocks | 0 | 0 |
Debtors | £27,000.00 | £132,000.00 |
Cash & Equivalents | £1.56 m | £478,000.00 |
Other Assets | 0 | 0 |
Total Assets | £1.69 m | £2.79 m |
Liabilities | 2023 | 2022 |
---|---|---|
Creditors within 1 year | £186,000.00 | £145,000.00 |
Creditors after 1 year | 0 | 0 |
Other Liabilities | 0 | 0 |
Total Liabilities | £186,000.00 | £145,000.00 |
Net assets | £1.51 m | £2.64 m |
Equity | 2023 | 2022 |
---|---|---|
Called up share capital | £37,000.00 | £35,000.00 |
Share Premium | £35.34 m | £34.92 m |
Profit / Loss | -£1.76 m | -£963,000.00 |
Other Equity | £1.51 m | £2.64 m |
Preference & Minorities | 0 | 0 |
Total Capital Employed | £1.51 m | £2.64 m |
Ratios | 2023 | 2022 |
---|---|---|
Debt Ratio | 0 | 0 |
Debt-to-Equity | 0 | 0 |
Assets / Equity | 1.1625 | 1.1625 |
Cash / Equity | 1.0277 | 1.0277 |
EPS | £-0.00 | £-0.00 |
Cash Flow | 2023 | 2022 |
---|---|---|
Cash from operating activities | -£639,000.00 | -£872,000.00 |
Cashflow before financing | -£334,000.00 | -£277,000.00 |
Increase in Cash | -£334,000.00 | -£397,000.00 |
Income | 2023 | 2022 |
---|---|---|
Turnover | 0 | 0 |
Cost of sales | 0 | 0 |
Gross Profit | 0 | 0 |
Operating Profit | -£1.76 m | -£963,000.00 |
Pre-Tax profit | -£1.76 m | -£963,000.00 |
Cizzle Biotechnology Holdings PLC Company Background
Sector | Healthcare |
---|---|
Activities | Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stableplasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer. |
Latest Interim Date | 30 Sep 2024 |
Latest Fiscal Year End Date | 27 Apr 2023 |
Cizzle Biotechnology Holdings PLC Directors
Appointed | Name | Position |
---|---|---|
2011-08-09 | Mr. John Corelli James Thynne | Non-Executive Director |
2011-08-09 | Mr. Gareth Jones | Executive Director,Chief Technology Officer |
2019-04-30 | Mr. Jonathan David Freeman | Non-Executive Director,Chairman |
2011-08-09 | Mr. Simon John Gibson OBE | Non-Executive Director |
2016-05-31 | Dr. Andrew William Nelson OBE | Non-Executive Director |
2011-08-09 | Mr. Owen Griffith Ronald Jones | Non-Executive Director |
2011-08-09 | Mr. Giles Alexander Davies | Executive Director,Chief Financial Officer and Co Secretary |
2012-06-27 | Mr. Ceri Jones | Executive Director,Chief Financial Officer and Company Sec |
2024-04-30 | Dr. Allan John Syms | Executive Director,Chairman |
2011-08-09 | Mr. Shaun Piers Oxenham | Executive Director,Chairman |
2019-07-04 | Dr. James Stuart Mckenzie | Executive Director,Chief Executive Officer |
2019-07-04 | Dr. Majid Zoorob | Executive Director,Chief Technical Officer |
2015-11-20 | Mr. Russell Anthony Banks | Executive Director,Chief Financial Officer |
2016-06-23 | Mr. Philip Antony Marshall | Non-Executive Director |
2024-04-30 | Mr. John Michael Treacy | Non-Executive Director |
2024-04-30 | Mr. Dawn Alison Coverley | Non-Executive Director |
2024-04-30 | Mr. Nigel Ronald Lee | Executive Director,Finance Director |
Cizzle Biotechnology Holdings PLC Contact Details
Company Name | Cizzle Biotechnology Holdings PLC |
---|---|
Address | Heslington Hall, Heslington, York, YO10 5DD |
Telephone | +44 207264444 |
Website | https://www.cizzlebiotechnology.com |
Cizzle Biotechnology Holdings PLC Advisors
Stockbroker | Peterhouse Corporate Finance Ltd |
---|---|
Phone | +44 2074690930 |
Fax | +44 2072209798 |
Nominated Adviser | Northland Capital Partners |
---|---|
Phone | +44 2038616625 |
Fax | +44 2076005975 |
Stockbroker | Northland Capital Partners |
---|---|
Phone | +44 2038616625 |
Fax | +44 2076005975 |
Solicitor | Greenaway Scott LLP |
---|---|
Phone | 029 2009 5500 |
Registrar | Link Asset Services |
---|---|
Phone | +44 8716640300 |
Fax | +44 2086392342 |
Financial PR Adviser | Instinctif Partners |
---|---|
Phone | +44 2074572020 |
Bank | Barclays Bank PLC |
---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine

Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
Energean PLC | 868.50 | 6.50 |
Pollen Street Group Limited | 762.00 | 6.42 |
Crest Nicholson Holdings PLC | 175.70 | 6.04 |
Metro Bank Holdings PLC | 93.80 | 4.80 |
Ao World PLC | 100.60 | 4.79 |
Smiths Group PLC | 2,090.00 | 4.66 |
Fallers
Company | Price | % Chg |
---|---|---|
Kingfisher PLC | 251.01 | -10.26 |
Ip Group PLC | 41.75 | -5.65 |
AJ Bell PLC | 399.00 | -4.55 |
Ferrexpo PLC | 61.80 | -4.04 |
Ocado Group PLC | 249.80 | -3.92 |
Firstgroup PLC | 163.80 | -2.90 |